Kitazato Corporation
368A・Prime Market・Precision Instruments
Kitazato Corporation
368A・Prime Market・Precision Instruments
Business
Kitazato Corporation is a medical device and reagent manufacturer specializing in advanced reproductive medicine centered on in vitro fertilization and micro-insemination. The company integrates domestic production at its Shizuoka head office plant for its full product lineup (Media (Reagents), Cryodevice (Cryopreservation Products), Medical Devices (Ovum Pick-up Needles, Catheters, etc.), and Micro Tools (Micro-insemination Products)) supporting the entire fertility treatment process from egg retrieval to cryopreservation and embryo transfer, supplying to approximately 110 countries and regions worldwide. Its main customers are hospitals and clinics both domestically and internationally, with overseas sales conducted through a network of approximately 80 distributor companies. In FY2026 (ending March 2026), net sales reached ¥10,947 million, with the overseas sales ratio reaching 66.6%.
Business Model
All products are manufactured domestically at the Shizuoka head office plant, including manual processes, ensuring quality control, and are sold to overseas medical institutions through approximately 80 distributors worldwide (a distributor-based approach). The core products are reagents and instruments consumed at each stage of fertility treatment, and repeat purchases linked to the number of treatment cycles support revenue stability. Overseas sales account for 66.6% of total sales, and the company is expanding its sales regions, centered on Europe, the United States, and India.
Company Strengths
A key differentiator from competitors is the ability to provide, as a single group, a product portfolio covering the entire workflow from oocyte retrieval, sperm washing, fertilization, and culture to cryopreservation and embryo transfer. The lineup consists of four categories—Media (Reagents), Cryodevice (Cryopreservation Products), Medical Devices, and Micro Tools (Micro-insemination Products)—and in FY2026 (ending March 2026), all categories except Cryodevice (Cryopreservation Products) achieved year-on-year revenue growth.
The operating margin for FY2026 (ending March 2026) stood at an extremely high 53.5% (operating profit of ¥5,858 million on net sales of ¥10,947 million). All products are manufactured at the company's own domestic factories, and a consumables-centered, repeat-purchase model stabilizes the cost structure. The financial base is also solid, with an equity ratio of 93.2% and cash and cash equivalents of ¥13,414 million.
The company has established a sales network spanning approximately 110 countries and regions worldwide, supplying products to local medical institutions through approximately 80 distributors. Sales in major regions are expanding steadily, with Europe at ¥3,990 million (up 15.7% year on year), the United States at ¥1,120 million (up 9.6%), and India at ¥593 million (up 26.9%). Ongoing efforts to obtain regulatory approvals in each country form a barrier to entry for new market participants.
ENVALITH's Perspective
Performance Trend
In FY2026 (ending March 2026), revenue was ¥10,947 million (up 6.3% year on year), operating profit was ¥5,858 million (up 1.3%), ordinary profit was ¥5,903 million (up 2.4%), and net income attributable to owners of parent was ¥3,895 million (up 2.8%), turning around from declines in each profit stage in the previous period to growth. Overseas revenue of ¥7,287 million (up 7.1%) was the driving force, with strong performance in Europe, the US, and India. China declined by 22.5% due to a rebound effect from spot sales in the previous period. Gross profit margin fell to 66.0% (from 67.7% in the previous period), and SG&A expenses also increased to ¥1,355 million (from ¥1,191 million in the previous period), but ordinary profit was supported by an increase in non-operating income, including foreign exchange gains of ¥68 million. Operating cash flow improved to ¥3,870 million (from ¥3,526 million in the previous period), and the fiscal year-end cash balance grew to ¥13,414 million.
Growth Strategy
Sustained growth through deeper customer development in Europe, the U.S., and India, combined with product lineup expansion and progress on regulatory certifications
Demand for Media (Reagents) and Cryodevice (Cryopreservation Products) expanded steadily through new customer acquisition and new product rollouts. European sales in FY2026 (ending March 2026) reached ¥3,990 million (up 15.7% year on year). The Company aims for further growth through expanding its product lineup and promoting the acquisition of regulatory certifications.
In the U.S., sales reached ¥1,120 million (up 9.6% year on year) driven by progress in customer development, while in India, continued rapid growth resulted in sales of ¥593 million (up 26.9% year on year). With a view to mid- to long-term growth, the Company is promoting the development of its sales and supply systems.
In line with strengthening overseas expansion, the Company actively invested in conference exhibition costs and costs for acquiring certifications in various countries. SG&A expenses in FY2026 (ending March 2026) increased to ¥1,355 million (up ¥163 million year on year). Progress in certification acquisition directly leads to expanded access to new markets and new customers.
In addition to stable demand for Medical Devices (Ovum Pick-up Needles, Catheters, etc.), strengthened sales activities including thorough follow-up with both new and existing customers led to domestic sales of ¥3,660 million (up 4.7% year on year) in FY2026 (ending March 2026). The Company will continue to develop products based on customer needs amid an ongoing competitive environment.
Last updated: July 19, 2026